Stock Alert: NVAX Up After NanoFlu Meets All Primary Endpoints In Phase 3 Trial

Shares of Novavax Inc. (NVAX) are surging over 30% in pre-market today, after the company announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant, in adults aged 65 and older.

from RTT - Before the Bell https://ift.tt/33FYx8F
via IFTTT